FATE Earnings Date & History
Fate Therapeutics Inc (NASDAQ NMS - GLOBAL MARKET) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Aug 19, 2026 at 7:17 PM ET
Fate Therapeutics Inc
Biotechnology
- Next earnings date
- Wednesday, November 11, 2026
- Reporting session
- Time TBD
- EPS estimate
- $-0.28
- Revenue estimate
- $1.4M
FATE earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Thursday, August 13, 2026 | Q2 2026 | $-0.27 | $-0.25 | +8.5% | $2.1M |
| Wednesday, May 13, 2026 | Q1 2026 | $-0.29 | $-0.26 | +9.0% | $1.3M |
| Thursday, February 26, 2026 | Q4 2025 | $-0.28 | $-0.27 | +1.9% | $1.4M |
| Thursday, November 13, 2025 | Q3 2025 | $-0.30 | $-0.27 | +9.1% | $1.7M |
| Tuesday, August 12, 2025 | Q2 2025 | $-0.35 | $-0.29 | +17.0% | $1.9M |
What the market is watching in FATE's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
- When is the next FATE earnings date?
- Fate Therapeutics Inc is scheduled to report on Wednesday, November 11, 2026 (Time TBD). Dates can change until the company confirms them.
- Does FATE report before or after the market?
- The next report is scheduled time tbd.
- What EPS is expected for FATE?
- Consensus EPS for the upcoming quarter is $-0.28, on revenue of $1.4M.
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
FATE earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.